Evaluate recent clinical trial data focused on the safety and efficacy of novel therapeutic agents and combination strategies that target the tumor microenvironment in hematologic malignancies
Describe the impact of large-scale immune profiling efforts on the development of novel therapeutic targets
Explore how emerging pathways and strategies targeting the immune microenvironment are used to inform and optimize precision medicine
Gain insights on the role of the tumor microenvironment in solid tumors and evaluate appropriate agents that promote tumor regression
Foster collaboration between academic and industry researchers to evaluate novel therapeutic approaches in hematologic malignancies
Agenda is subject to change
Thursday, September 22
Friday, September 23
Saturday, September 24
Thursday, September 22
Duration
Topic
3:00 PM – 3:05 PM
Welcome and Introductions
3:05 PM – 3:20 PM
Presentation: Translational Workshop on Hematologic Malignancies – Lessons Learned Over the Last 10 Years
Kieron Dunleavy, MD (Georgetown University)
3:20 PM – 3:50 PM
Keynote: Impact of the Microenvironment on CAR T-cells
3:50 PM – 4:05 PM
Presentation: The Role of the Microenvironment in Tumor Progression and Treatment Outcomes Kenneth Anderson, MD (Dana-Farber Cancer Institute)
4:05 PM – 4:25 PM
Breakout Session: Large-Scale Immune Profiling in Hematologic Malignancies
Microenvironment and Epigenetic Regulation in Lymphoma
Industry Perspectives
4:25 PM – 5:10 PM
Summary of Discussion to Large Group
5:10 PM – 5:25 PM
Presentation:Barriers in Eradicating Extramedullary B-ALL with CAR T-cell therapy
Nirali Shah, MD (National Cancer Institute)
5:25 PM – 5:40 PM
Presentation: Role of Non-coding Mutations Targeting Super-Enhancers in Lymphoma Laura Pasqualucci, MD (Columbia University)
5:40 PM – 5:45 PM
Wrap Up and Adjourn
7:00 PM – 10:00 PM
Welcome Dinner
Friday, September 23
Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Emerging Concepts in Immune Regulation and Targeting in Lymphoma
David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center)
9:15 AM – 9:30 AM
Presentation: Waldenstrom’s Macroglobulinemia
9:30 AM – 9:50 AM
Breakout Session: Recent Advances in Characterizing the Microenvironment in Lymphoma
Treatment Options for Patients with Richter’s Transformation
Review of Current Clinical Trial Data of CAR T, BTKi, and Bispecifics
Sequencing Immunotherapy and Novel Combination Strategies
Industry Perspectives
9:50 AM – 10:35 AM
Summary of Discussion to Large Group
Moderated by Loretta Nastoupil, MD (MD Anderson Cancer Center)
10:35 AM – 10:55 AM
Industry Presentation
10:55 AM – 11:10 AM
Coffee Break
11:10 AM – 11:25 AM
Presentation: Novel Therapeutic Strategies That Utilize the Microenvironment to Improve Outcomes in Leukemia
Jan Burger, MD, PhD (MD Anderson Cancer Center)
11:25 AM – 11:45 AM
Breakout Session & Discussion: Current Advances Targeting Immunity and the Microenvironment in Leukemia
BTK Inhibitors in CLL
Role of the Microenvironment in Resistance to Therapy in AML
Industry Perspectives
11:45 AM – 12:30 PM
Summary of Discussion to Large Group
12:30 PM – 1:30 PM
Lunch
1:30 PM – 2:00 PM
Pathogenesis of LGL Leukemia Tom Loughran, MD (University of Virginia)
2:00 PM – 2:15 PM
Presentation: New Approaches for CAR T-cell Therapy in Hematologic Malignancies (bi-specific antibodies, targeting ALL/CD-22/CD-19) Jennifer Brudno, MD (National Cancer Institute)
12:30 PM – 1:30 PM
Lunch
1:30 PM – 1:45 PM
Presentation: Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine Presenter TBC
2:15 PM – 2:35 PM
Breakout Session: Unifying Immune Therapy with Precision Medicine
Incorporating ctDNA into Clinical Practice
Interplay of Genomics with the Tumor Microenvironment
Industry Perspectives
2:35 PM – 3:20 PM
Summary of Discussion to Large Group
Catherine Bollard, MD, MBChB (Children’s National Hospital)
3:20 PM – 3:35 PM
Coffee Break
3:35 PM – 3:50 PM
Industry Presentation
3:50 PM – 4:05 PM
Immune Microenvironment in Solid Tumors
Chrystal Paulos, PhD (Emory University)
4:05 PM – 4:20 PM
FDA Presentation
Bindu Kanapuru, MD (Food and Drug Administration/CDER/OHOP)
3:30 PM – 4:00 PM
Pathogenesis of LGL Leukemia
Tom Loughran, MD (University of Virginia)
4:20 PM – 5:00 PM
Reception: Poster Display and Discussion
7:00 PM – 9:00 PM
Dinner
Saturday, September 24
Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Insights into the Immune Microenvironment in Multiple Myeloma
Madhav Dhodapkar, MBBS (Emory University)
9:15 AM – 9:35 AM
Breakout Session: Targeting the Tumor Microenvironment in Multiple Myeloma
Impact of the Immune Microenvironment on CAR T Treatment, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibodies, ADCs, CELMoDs, and IMiDs
Sequencing Immunotherapy and Novel Combination Strategies
Industry Perspectives
9:35 AM – 10:20 AM
Summary of Discussion to Large Group Moderated by Sagar Lonial, MD, FACP (Emory University)
10:20 AM – 10:50 AM
Keynote: Immune Microenvironment and Cell medicine Helen Heslop, MD, DSc (Baylor College of Medicine)
10:50 AM – 11:50 AM
Working Session
Interactive, open discussion to develop an article or other output that recaps the key findings from the meeting
11:50 AM – 12:00 PM
Closing Remarks, Action Items for 2023, and Adjourn Sagar Lonial, MD, FACP (Emory University)
Thursday, September 22
Duration
Topic
3:00 PM – 3:05 PM
Welcome and Introductions
3:05 PM – 3:20 PM
Presentation: Translational Workshop on Hematologic Malignancies – Lessons Learned Over the Last 10 Years
Kieron Dunleavy, MD (Georgetown University)
3:20 PM – 3:50 PM
Keynote: Impact of the Microenvironment on CAR T-cells
Presenter TBC
3:50 PM – 4:05 PM
Presentation: The Role of the Microenvironment in Tumor Progression and Treatment OutcomesKenneth Anderson, MD (Dana-Farber Cancer Institute)
4:05 PM – 5:10 PM
Breakout Session & Discussion: Large-Scale Immune Profiling in Hematologic Malignancies
Microenvironment and Epigenetic Regulation in Lymphoma
Industry Perspectives
4:25 PM – 5:10 PM
Summary of Breakouts/Large Group Discussion
5:10 PM – 5:25 PM
Immune Microenvironment in Solid Tumors
Chrystal Paulos, PhD (Emory University)
5:25 PM – 5:40 PM
Panel Discussion and Q&A
5:40 PM – 5:45 PM
Wrap Up and Adjourn
7:00 PM – 10:00 PM
Welcome Dinner
Friday, September 23
Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Emerging Concepts in Immune Regulation and Targeting in Lymphoma
David Maloney, MD, PhD (Fred Hutchinson Cancer Research Center)
9:15 AM – 10:20 AM
Breakout Session & Discussion: Recent Advances in Characterizing the Microenvironment in Lymphoma
Treatment Options for Patients with Richter’s Transformation
Review of Current Clinical Trial Data of CAR T, BTKi, and Bispecifics
Sequencing Immunotherapy and Novel Combination Strategies
Industry Perspectives
9:35 AM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:40 AM
Industry Presentation
10:40 AM – 10:55 AM
Coffee Break
10:55 AM – 11:10 AM
Presentation: Novel Therapeutic Strategies That Utilize the Microenvironment to Improve Outcomes in Leukemia
Jan Burger, MD, PhD (MD Anderson Cancer Center)
11:10 AM – 12:15 PM
Breakout Session & Discussion: Current Advances Targeting Immunity and the Microenvironment in Leukemia
BTK Inhibitors in CLL
Role of the Microenvironment in Resistance to Therapy in AML
Industry Perspectives
11:30AM – 12:15 PM
Summary of Breakouts/Large Group Discussion
12:15 PM – 12:30 PM
Presentation: New Approaches for CAR T-cell Therapy in Hematologic Malignancies(bi-specific antibodies, targeting ALL/CD-22/CD-19) Jennifer Brudno, MD (National Cancer Institute)
12:30 PM – 1:30 PM
Lunch
1:30 PM – 1:45 PM
Presentation: Tumor Microenvironment and Targeting Strategies in an Era of Precision MedicinePresenter TBC
1:45 PM – 2:50 PM
Breakout Session & Discussion: Unifying Immune Therapy with Precision Medicine
Incorporating ctDNA into Clinical Practice
Interplay of Genomics with the Tumor Microenvironment
Industry Perspectives
2:05 PM – 2:50 PM
Summary of Breakouts/Large Group Discussion
2:50 PM – 3:00 PM
Coffee Break
3:00 PM – 3:15 PM
Industry Presentation
3:15 PM – 3:30 PM
FDA Presentation
Bindu Kanapuru, MD (Food and Drug Administration/CDER/OHOP)
3:30 PM – 4:00 PM
Pathogenesis of LGL Leukemia
Tom Loughran, MD (University of Virginia)
4:00 PM – 5:00 PM
Poster Display and Discussion Session
7:00 PM – 9:00 PM
Dinner Reception
Saturday, September 24
Duration
Topic
8:30 AM – 9:00 AM
Breakfast
9:00 AM – 9:15 AM
Presentation: Insights into the Immune Microenvironment in Multiple Myeloma Madhav Dhodapkar, MBBS (Emory University)
9:15 AM – 10:20 AM
Breakout Session & Discussion: Targeting the Tumor Microenvironment in Multiple Myeloma
Impact of the Immune Microenvironment on CAR T Treatment, Proteasome Inhibitors, Anti-CD38 Monoclonal Antibodies, ADCs, CELMoDs, and IMiDs
Sequencing Immunotherapy and Novel Combination Strategies
Industry Perspectives
9:35 PM – 10:20 AM
Summary of Breakouts/Large Group Discussion
10:20 AM – 10:50 AM
Keynote: Immune Microenvironment and Cell medicineHelen Heslop, MD, DSc (Baylor College of Medicine)
10:50 AM – 11:50 AM
Working Session
Interactive, open discussion to develop an article or other output that recaps the key findings from the meeting
11:50 AM – 12:00 PM
Closing Remarks, Action Items for 2023, and AdjournSagar Lonial, MD, FACP (Emory University)